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Abstract
Background: Successful pregnancy via in vitro fertilization (IVF) depends on the recovery of an adequate number
of healthy oocytes and on blastocyst implantation following uterine transfer. Two hormones, LH and hCG, utilize a
common LH/hCG receptor (LHCGR), variations in which have profound implications in human reproduction.
Soluble LHCGR (sLHCGR) is released from experimental cell lines and placental explants and it can be detected in
the follicular fluid and serum.
Methods: To evaluate the impact of circulating soluble LHCGR (sLHCGR) in fertility treatment, we measured
sLHCGR and LH-sLHCGR complex in serum from women seeking IVF using specifically developed quantitative
enzyme-linked immunosorbent assays (ELISA). Following an IVF cycle of treatment, patients were grouped
according to oocyte yield into low (lower than or equal to 7 oocytes), intermediate (8-14 oocytes) and high
(greater than or equal to 15 oocytes) responders and pregnancy outcome noted.
Results: Pre-treatment sLHCGR identified many women at risk of ovarian hyperstimulation. Low levels of sLHCGR
were associated with pregnancy in both high and low responders but sLHCGR did not significantly affect the
treatment outcome of intermediate responders. Low responders who failed to become pregnant had high levels
of circulating sLHCGR bound to LH (LH-sLHCGR).
Conclusions: Pre-treatment measurement of sLHCGR could be used to tailor individual fertility treatment programs
and improve outcomes by avoiding ovarian hyperstimulation and poor embryo implantation.
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Background
Given that about three-quarters of human embryos cre-
ated by assisted reproductive technology (ART) such as
IVF and ICSI fail to produce live births following uterine
transfer [1], there has been increasing interest in identify-
ing pre-treatment factors that may indicate the likelihood
of success with fertility treatments. The follicle stimulating
hormone [FSH] and luteinizing hormone [LH], play cen-
tral roles in the maturation of the ovarian follicles and
ovulation. Following ovulation, the remaining cells of the
follicle are luteinized by LH and secrete progesterone plus
oestradiol which are necessary for implantation of the
embryo [2]. One of the important aspects of the female
reproductive cycle is that ovulation is controlled by a pul-
satile secretion of LH (LH surge) that is subject to indivi-
dual variation [3]. In controlled ovarian stimulation
(COS), this variability of ovarian activities is temporarily
eliminated by GnRH agonists/antagonists, while at the
same time the ovarian functions are regulated by exogen-
ously injected FSH and LH/hCG [4-7].
In addition to routine estimation of LH and FSH, the
serum concentrations of anti-mullerian hormone (AMH)
are often measured prior to COS. While LH or FSH alone
or together provide a measure of the ovarian activity,
AMH is the reliable marker for functional ovarian reserve
[8]. Moreover, high AMH levels (> 45 pmol/L) are indica-
tive of polycystic ovary (PCO) and these patients are
usually susceptible to ovarian hyperstimulation syndrome
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concentrations, being independent of the phase of the
reproductive cycle, also appear to have some predictive
value with respect to the pregnancy outcome [9,10].
The receptors expressed on the surface of target cells for
LH and human chorionic gonadotrophin (hCG) binding
and signalling are identical and are therefore described as
the LH/hCG receptor or LHCGR [11]. In addition to
ovary and testis, various isoforms of LHCGR are expressed
almost ubiquitously in primary and secondary reproduc-
tive organs (uterus, fallopian tube, placenta and breast)
and in a variety of extragonadal tissues including vascular
endothelial and smooth muscle cells, brain, lymphocytes,
macrophages, skin as well as foetal tissues [12,13]. The
physiological significance of the extragonadal expression
of LHCGR remains unexplained.
The earliest experimental evidence of the cell-free exis-
tence of LH receptor was its hCG-affinity purification
from porcine follicular fluid [14]. The detection of a Mr
80-90K LH-LH receptor complex from Leydig cell culture
media [15] and a Mr 30-60K LH-receptor binding protein
in serum from uremic boys suffering from hypogonadism
provided further clues to the extracellular appearance of
soluble LH receptor. Notably, both soluble LH receptor
and the hCG-receptor complexes have been shown to be
released from cells transfected with cloned LH receptor
[16-18]. However, the clinical significance of the cell-free
soluble LHCGR remained unknown due to the lack of a
convenient experimental system for quantitative estima-
tion of the soluble receptor in body fluids.
We have recently shown that soluble LH/hCG receptor
(sLHCGR) is released from LHCGR-transfected cells, pla-
cental explants [19] and into the bloodstream of pregnant
w o m e n .H e r e ,w ed e s c r i b et h ed e v e l o p m e n ta n du s eo f
quantitative ELISA assays for the measurement of
sLHCGR and hormone-receptor complex (LH-sLHCGR)
in the serum of women presenting for IVF treatment.
The assays described detect the analytes in follicular
fluid, serum and plasma samples from the same patient.
Our results demonstrate that women with high pre-treat-
ment serum sLHCGR or LH-sLHCGR are usually low
responders, produce reduced number of oocytes (≤ 5
oocytes) and are less likely to become pregnant. In addi-
tion, low to undetectable pre-treatment circulating
LHCGR/LH-receptor complex is associated with high
ovarian response (≥ 15 oocytes) and OHSS. The clinical
applications of these assays in predicting ovarian
response to fertility treatment and improving implanta-
tion potential following embryo transfer are discussed.
Methods
Antibodies
Purified LHR29 monoclonal antibody [19,20] was initially
provided by Dr Hugues Loosfelt (INSERM, France) and
subsequently the antibody producing clone was obtained
from ATCC (Clone ID CRL-2685). The epitope for the
LHR29 monoclonal antibody was mapped using LHCGR
recombinant proteins expressed in CHO cells [19]. It
resides within amino acid residues 229 to 291 of the N-
terminus extracellular domain (ECD) of LHCGR. A 19
amino acid residue LHCGR peptide (LHCGR 209-227;
Swissprot: locus LSHR_HUMAN, accession P22888) was
used to produce a second monoclonal antibody, clone
5A10C9. This antibody was purified from culture super-
natant by Protein A affinity chromatography. The mono-
clonal antibody against luteinizing hormone b (LH b)
clone 2LH2-L1 was obtained from HyTest Ltd. (Turku,
Finland). In addition to this, a variety of polyclonal anti-
bodies against LHCGR and monoclonal antibodies
against LH b were tested during assay development.
Antibodies were conjugated to Horse Radish Peroxidase
using a Lightning-Link HRP conjugation kit according to
the manufacturer’s instructions (Innova Biosciences,
Cambridge, UK). Briefly, 10 μL of LL-modifier was added
to 100 μg (100 μL) of affinity purified antibody and was
conjugated either for three hours or overnight before the
reaction was stopped using 10 μL of LL-Quencher
reagent for 30 minutes. Conjugated antibodies were sta-
bilized by the addition of 10 μL Peroxidase Stabilizer
(Cosmo Bio Co. Ltd., Japan) and stored at 4°C for up to
six months. The specificity of the assay was established
by a variety of controls including mock/LHCGR ECD-
expressing Chinese Hamster Ovary (CHO) cell extracts
and isotype-specific IgGs from rabbit, mouse and goat.
ELISA protein standards
The expression of soluble LHCGR (sLHCGR, N-term-
inal 336 residues of the ECD) as a thioredoxin fusion
protein in Escherichia coli (E. coli) bacteria carrying
mutations in both thioredoxin reductase (TrxB) and glu-
tathione reductase (gor) genes has been reported [21].
This chimeric sLHCGR was shown to have a similar
specificity and affinity for hCG as the intact native
LHCGR [21]. This protocol was therefore followed in
order to produce sLHCGR standard for ELISA assays.
Briefly, cDNA encoding the N-terminal 316 amino acid
residues of the LHCGR ECD was cloned into the Eco RI
(5’)a n dS a lI( 3 ’) sites of pET32a(+) vector (Novagen,
USA) to generate an E. coli bacterial clone. With respect
to orientation, the clone contained two histidine repeat
tags, one at the C-terminus and the other sandwiched
between the LHCGR ECD and TrxB at the N-terminus.
The DNA sequence of the insert was confirmed prior to
transformation of E. coli (Origami strain trxB gor (DE3)
pLysS (kanR, tetR, CmR), Novagen, USA). The protocol
for expression of the LHCGR fusion protein and affinity
purification through Ni-NTA resin column (Qiagen)
were exactly as described [21]. The estimated relative
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of 6.15. The affinity purified protein was > 90% pure
and the yield varied from 6.63 to 7.34 mg/L. The affinity
purified protein was stored at a concentration of
0.255 mg/mL (4.4316 μM) in 25% glycerol at -20°C.
Unlike sLHCGR standard, the creation of an in vitro
LH-LHCGR complex standard was less straight forward.
Previous work [22] had established that a tethered single
chain hCG-LHCGR cloned in baculovirus and expressed
in insect cells was functional with respect to ligand-recep-
tor interaction. Moreover, this yoked hCG-LHCGR ECD
was shown to be secreted from insect cells at levels
20-fold higher than conventional eukaryotic expression
systems [22]. Our goal was to produce a yoked LH b-
sLHCGR single chain protein containing the epitopes
recognized by both LH b and LHCGR antibodies. There-
fore, the open reading frame encoding the entire 141
amino acids of hLH b was synthesized (Source: Uni-
ProtKB/Swiss-Prot;Acc:P01229). A linker sequence encod-
ing the hCG b C-terminal peptide (CTP, constituting
amino acids 116-145 of hCG b)w a sl i g a t e da tt h e3 ’ end
of the above construct (hLH b-CTP). The addition of the
CTP sequence has been shown to stabilize the expressed
fusion protein [22]. A cDNA clone encoding 115 to 291
amino acid residues of the N-terminal end of LHCGR
ECD was produced. The hLH b-CTP was ligated to the 5’-
end of the modified LHCGR and cloned into p3XFLAG-
CMV-14 vector to create an E. coli bacterial clone. The
hLH b-sLHCGR complex was first expressed in trans-
fected CHO cells and the specificity of the yoked hLH b-
sLHCGR protein was established by testing anti-LHCGR,
anti-hLH b and anti-FLAG monoclonal antibody binding
of the recombinant and mock transfected CHO extracts in
plate assays. For large scale production, the protein was
expressed in baculovirus transfected sf9 insect cells in
order to ensure correct eukaryotic glycosylation of the LH
moiety of the fusion protein. Purification was achieved by
loading the culture supernatant onto FLAG M2 affinity
gel, followed by elution with TBS (50 mM Tris-HCl, 150
mM NaCl, pH 7.4) containing 200 ng/μL FLAG peptide
(synthetic octapeptide, N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-
Lys-C molecular weight 1013.0). The yield of the yoked
hLH b-sLHCGR protein was 0.43 mg/L with an estimated
purity of 50%. The relative molecular mass of the fusion
protein backbone was 40850 (pI 6.65). The molecular
mass of glycosylation was not included in quantification
calculations. The affinity purified protein was stored at a
concentration of 52.5 μg/mL (1.2851 μM) in 25% glycerol
at -20°C.
ELISA standards were two-fold serially diluted with
extensive mixing through 25 mM Bicine (Fluka), 50 mM
Tris pH 7.8, 170 mM NaCl in uncoated vinyl mixing plates
(Costar, UK) immediately prior to loading onto a pre-
coated ELISA plate. The concentration of the first dilution
for each standard was as follows: sLHCGR, 39.88 pico-
moles per mL; LH-sLHCGR, 20.5616 picomoles per mL.
ELISA procedure
Standard ELISA methods were followed for quantitative
analysis of the sLHCGR and LH-LHCGR protein in the
serum samples. Details for antibody coating of ninety-
six-well plates, antigen binding, antigen detection and
data analysis will be published elsewhere (manuscript in
preparation).
Human sera and sLHCGR and LH-sLHCGR protein
standards show dilution dependent effects in ELISA
The specificity of the capture-detection system for ELISA
was first established employing anti-FLAG affinity puri-
fied recombinant LHCGR proteins (LHCGR ECD, amino
acid residues 1-291) expressed in CHO cells [19]. The
estimated purity of this affinity purified LHCGR standard
from CHO cell extracts was 40-50%, as judged by SDS-
PAGE and western blots. Subsequently, bacterially
expressed affinity purified recombinant LHCGR ECD
which had a consistent purity of > 90% (see Methods)
was used for all sera analyses( F i g u r e1 a ) .T h i ss L H C G R
standard produced a linear dilution dependent response
when LHR29 and 5A10C9 were used as capture and
detection antibodies, respectively. The sensitivity (limit of
detection) of the assay was less than 0.62 pmol/mL (Fig-
ure 1b). The dilution dependent linear response of the
sLHCGR ELISA system was further established by exam-
ining the dilution effect of three early pregnancy sera
(Figure 1c). The LH-sLHCGR standard, created by
tethering LH to a portion of the LHCGR ECD was
expressed in insect cells to preserve glycosylation and the
anti-FLAG affinity purified fusion protein was approxi-
mately 50% pure (see Methods, Figure 1d). Serially
diluted LH-sLHCGR protein was captured by 5A10C9
and was detected by HRP-conjugated anti-LHb monoclo-
nal antibody. Based on the estimated purity of the stan-
dard, the sensitivity (limit of detection) of the assay was <
0.64 pmol/mL (Figure 1e). Although the affinity purified
LH-sLHCGR standard appeared as three bands on wes-
tern blot (Figure 1d), it was unclear whether all three
were active on ELISA and whether they might be multi-
mers of the protein standard, therefore purity calcula-
tions were based solely on the band of expected relative
molecular mass (40850). In addition, the contribution of
glycosylation to molecular mass was not included in
molarity calculations. All measurements for LH-sLHCGR
complex are therefore conservative, but consistent for
inter-comparison of sera values. The dilution dependent
linear response of the LH-sLHCGR ELISA system was
further established by examining the dilution effect of
sera from three female patients seeking fertility treatment
(Figure 1f).
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This prospective study had a broad aim to examine the
association of pre-treatment serum sLHCGR and LH-
sLHCGR concentrations with treatment outcome for
patients seeking fertility treatment at Midland Fertility
Services (MFS), Aldridge, UK. This study was approved
by West Midlands Research Ethics Committee, UK.
Written informed consent was obtained from the parti-
cipants of this study, with the understanding that con-
sent could be withdrawn by the patient at any time
without prejudice.
Statistical analysis
The means, standard deviations, variance (anova), confi-
dence intervals (CI) for each data set were computed
using Analysis ToolPak (ATP) software. The significance
of differences between groups was evaluated using two-
sample paired t-test. ELISA assay standard curves were
generated following examination of the natural log plot of
the optical density (OD) at 450-620 nm for all the stan-
dard points to ensure that the points form a straight line.
The graph plotting and statistical analyses were carried
out using the R statistical environment and the ggplot2
package running on a Linux operating system. Correla-
tion testing was performed using the Pearson product
moment method which is available in the standard R
package. General file manipulations and data cleaning
were implemented using the Awk programming language
or custom programs written in Python. All software was
open source and is freely available from publicly accessi-
ble sites.
Results
Clinical samples; regimens, oocyte yields, pregnancy
outcomes and data collection
Baseline serum samples (cycle day 2-5) were obtained
from 276 women who attended the clinic. Of these, 161
patients enrolled in an IVF or ICSI/IVF cycle. All samples
irrespective of fertility treatment, were assayed for FSH,
LH, AMH, sLHCGR and LH-sLHCGR; however, AMH
together with LH data were not available for seven
patients.
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Figure 1 The sensitivity of sLHCGR and LH-sLHCGR ELISAs. The purity of the affinity purified recombinant LHCGR protein extracellular
domain (a, indicated by an arrow) and LH-sLHCGR (d, indicated by arrows) proteins were examined in SDS-polyacrylamide gels-stained with
coomassie blue. The small arrows above the major band in d) are either glycosylated or dimers because these bands react with anti-FLAG and
LHR29 monoclonal antibodies. The sensitivity of the ELISAs was verified by linear responses to the dilution effect of sLHCGR (b) and LH-sLHCGR
protein calibrators (e). The sensitivities of these assays were further examined by assaying serially diluted serum samples from three patients with
known concentration of sLHCGR (c) and LH-LHCGR (f). Each data point in b and e represents mean value obtained from six independent
dilution of the standards.
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oocyte collection and were stored exactly as serum sam-
ples. For patients undergoing fertility treatment, the hor-
mone data (FSH, LH, AMH) in conjunction with
information on age, antral follicle count (AFC) and Body
Mass Index (BMI) were used to determine the optimum
dose for ovarian stimulation assuming a desired oocyte
yield of 8-14 mature oocytes. Information on sLHCGR or
LH-sLHCGR serum concentration, where known, was not
used to alter patient treatment regimens. The majority of
patients undertook a ‘long-protocol’ stimulation regimen
with GnRH agonist down-regulation commenced in the
luteal phase. Patients with a high baseline FSH level (> 10
IU/L) undertook a ‘short protocol’ stimulation regimen
with GnRH antagonist control. Despite the attempt to ‘nor-
malise’ the response in terms of oocyte yield, there was a
wide variation with respect to the oocyte yield (range 1-39)
and as expected there was a strong positive correlation
between oocyte yield and AMH levels (see below). Given
that there are no absolute cut-off values for ‘low” and ‘high
responders’ the patients were divided into three groups:
High responders, with ≥ 15 oocytes; intermediate respon-
ders with 8-14 oocytes and low responders with a yield of
≤7 oocytes; 48.6 to 70.4% of the oocytes were fertilized; >
95% of the patients had two fresh embryos transferred.
Each group was further sub-divided by the pregnancy out-
come (i.e. pregnant or non-pregnant). In the high response
group (54 patients), 17 (31.5%) became pregnant, 14 did
not become pregnant and 23 (42.6%) had all their embryos
frozen due to a significant risk of OHSS. In the intermedi-
ate responder group (54 patients), 27 (50%) became preg-
nant. In the low response group (53 patients), 13 (24.5%)
became pregnant and 40 did not. Pregnancy was initially
c o n f i r m e db yh C Gt e s ta n db yu l t r a s o u n ds c a ns h o w i n g
fetus at around 7 wk following transfer.
sLHCGR is detected in follicular fluid, plasma and serum
In a comparative analysis, 8 pairs of pre-treatment
serum and follicular fluid (following LH or hCG ovarian
stimulation) from 8 patients undergoing fertility treat-
ment were assayed for sLHCGR. Although the mean
concentration of sLHCGR was always higher (≥1.9-fold)
in the serum compared to the follicular fluid, concentra-
tions in each followed a similar pattern. In some
patients sLHCGR was undetectable in both serum and
follicular fluid (data not shown). Concentrations of
sLHCGR in paired plasma and serum samples from
either pregnant or non-pregnant women were generally
comparable (data not shown).
Low and high serum AMH are inversely related to pre-
treatment LHCGR/LH-LHCGR concentrations
We examined the relative concentrations of serum FSH,
sLHCGR and LH-sLHCGR at very low and high AMH
levels. As expected, at very low AMH (0.3-2.2 pmol/L), the
FSH concentration was significantly high (P < 0.001) with
a correlation coefficient of r = -0.62 (Figure 2a). Moreover,
at these levels of AMH (≤ 4 pmol/L), the average FSH:LH
ratio was 2.3:1. At low AMH (≤ 4 pmol/L), the sLHCGR
concentrations were relatively high (> 20 pmol/mL) in
35.1% (
13/37) of patients (Figure 2b) with correlation of r =
-0.25 (P = 0.14). Serum sLHCGR was similarly inversely
related (r = -0.49, P = 0.03) at AMH range of ≥45 pmol/L
(Figure 2d). In ~70% (
16/23) of these women, the serum
LH-sLHCGR was either undetectable (52.2%) or ≤1.0
pmol/mL (17.4%, see below). Moreover, unlike the low
AMH group (≤ 4 pmol/L), FSH failed to significantly cor-
relate with AMH (Figure 2c) and the FSH:LH ratio in
patients with high AMH (≥45 pmol/L) was 1.2:1 (data not
shown). Together, these results suggest that low FSH:LH
ratio (≤1:1) and undetectable or low sLHCGR/LH-
sLHCGR could be independent indicators of PCO/OHSS.
More than 30% of all patients tested have high serum
sLHCGR
To establish the prevalence and concentration range of
sLHCGR in women presenting for IVF treatment, early
cycle LH and sLHCGR levels were measured and com-
pared in 273 patients. The LH concentrations in 47%
(128 patients) and 46% (126 patients) of the samples
were 0.07-5.0 IU/L and 5.0-10.0 IU/L, respectively, while
the remaining 7% (19 patients) samples had > 10.0 IU/L
(Figure 3a). When compared, 52% (141 patients) and 16%
(45 patients) of the samples had serum sLHCGR of 0-9.9
pmol/mL and 10-20 pmol/mL, respectively (Figure 3b).
The remaining 32% (87 patients) had high concentrations
of sLHCGR (> 20 pmol/mL). High levels of early cycle
serum LH (≥10 IU/l) is usually associated with PCO and
susceptibility to heightened ovarian response on con-
trolled ovarian stimulation. Therefore, LH values > 9 IU/
L were compared with corresponding sLHCGR levels.
This analysis revealed that a negative correlation (r =
-0.397, P < 0.05) exists between concentrations of the
hormone and the soluble receptor (Figure 3c).
Age negatively correlates with pre-treatment sLHCGR
levels in non-OHSS women
Comparative analysis of AMH with age (range 21 to 47
yrs) on 269 women showed a correlation coefficient of r
= -0.411, confirming that the women in the higher age
group tend to have low AMH and reduced ovarian
reserve (data not shown). Based on this observation, we
asked whether pre-treatment sLHCGR correlates with
patient age. In those that were low responders age had a
significant impact on sLHCGR levels (Figure 4a-c). In
responders yielding ≤7 oocytes age was inversely corre-
lated with sLHCGR serum concentrations (r = -0.31, P =
0.05, Figure 4a). The age-effect became more evident
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≤ 4( r = -0.58, P = 0.01) oocytes (Figure 4b and 4c). This
suggests that the younger women who exhibit a low
response to COS would be more likely to have higher
serum sLHCGR than older women with the same oocyte
yield. Despite a lack of statistical significance (P =0 . 1 4 ) ,
it is interesting to note that an opposite correlation may
exist in the case of high responders (oocytes ≥ 15) who
exhibit OHSS; where age tended to be positively corre-
lated (r = +0.38) with sLHCGR concentrations (Figure
4d). Although not statistically significant, these results
m a yi n d i c a t et h a to l d e rw o m e nw i t hh i g hA F Cm i g h t
produce increased sLHCGR.
High pre-treatment serum sLHCGR is negatively
associated with oocyte yield
The relative yield of oocytes with respect to pre-treatment
sLHCGR was analysed in high (≥ 15 oocytes) and low (< 15
oocytes) responders by estimating the mean pmol/mL
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Figure 2 High serum FSH and low sLHCGR are inversely related to the pre-treatment serum AMH concentrations.T h eb a s a lA M H
concentrations at ≤ 4 pmol/L and ≥ 45 pmol/L were compared with corresponding FSH (a & c) and sLHCGR (b & d) concentrations. The
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ab c
Figure 3 A large proportion of women (> 30%) seeking fertility
treatment have > 20 pmol/mL, high pre-treatment sLHCGR. The
frequency and distribution of the concentrations of a) LH and b)
sLHCGR measured in 274 women seeking fertility treatment are
shown. Additionally, the LH concentrations ≥ 9.1 IU/L are inversely
related to the sLHCGR levels.
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Page 6 of 14sLHCGR per oocyte. In the high response group, women
with OHSS had the lowest amount of mean sLHCGR/
oocyte (0.58 pmol/mL), compared to non-pregnant (1.63
pmol/mL) and pregnant (0.77 pmol/mL) women (Figure
5a) Overall, for those who yielded > 15 oocytes, irrespective
of pregnancy or OHSS, the average level of sLHCGR per
oocyte was 0.99 pmol/mL. However, for those with 5-15
oocytes, both pregnant (5.7 pmol/mL) and non-pregnant
women (5.1 pmol/mL), had an average pre-treatment
sLHCGR concentration of 5.4 pmol/mL per oocyte (Figure
5b), which is over 5-fold more than those yielding 15 or
more oocytes. A similar analysis of the low responders
(oocytes ≤5) showed an even higher concentration of
sLHCGR per oocyte (8.7 pmol/mL/oocyte, Figure 5b).
These results may indicate that high pre-treatment
sLHCGR serum concentrations could alter functional LH
levels leading to an inhibition of the release of oocytes
following COS.
High LH-sLHCGR concentrations correspond with poor
treatment outcomes in low responders
The results shown above (Figure 5a and 5b) prompted
examination of the fraction of sLHCGR bound to the hor-
mone (LH-sLHCGR). The percentage of sLHCGR bound
to LH (LH-sLHCGR) with respect to the yield of oocytes
was analyzed for women who did not become pregnant
(Figure 5c) or who became pregnant (Figure 5d). Of those
who produced few oocytes (≤7) and who failed to become
pregnant, many had a larger fraction of the serum
s L H C G Rb o u n dt oL H .I n d e e d ,t h es a t u r a t i o nl e v e l so f
sLHCGR with LH (expressed as a percentage of sLHCGR/
LH-sLHCGR) in those who produced few oocytes (≤7)
and did not become pregnant were on average similar to
those with an intermediate number of oocytes (8-14
oocytes) who did become pregnant (15% versus 14%
respectively). Intriguingly, in those with an intermediate
number of oocytes (8-14 oocytes) who failed to become
pregnant, the average percentage saturation of sLHCGR
by LH was just 7%. By contrast, the average percentage
saturation of sLHCGR by LH in 12 of 13 women who pro-
duced few oocytes (≤7) and who did become pregnant was
6%, suggesting that a downward shift in sLHCGR satura-
tion levels may have enabled pregnancy in these low
responders. A similar shift in sLHCGR saturation levels
was noted in high responders, where those who became
pregnant had a lower saturation level (7%) compared to
those who failed to become pregnant (11%). Overall, these
data suggest that the saturation level of sLHCGR by LH
may be an important pregnancy determinant. High pre-
treatment LH saturation levels of sLHCGR, coupled with
either a low or high oocyte yield following COS, may be a
useful indicator of poor treatment outcome.
Low serum sLHCGR/LH-sLHCGR favours embryo
implantation in high and low responders
sLHCGR/LH-sLHCGR data for each clinical condition
(high, intermediate and low response) in the context of
each outcome (with pregnancy, without pregnancy or
OHSS) are presented in dot-plots (Figure 6) and summar-
ized in Table 1. Each condition has been represented by
two sets of data: with and without cut-off values (open cir-
cle and triangle, respectively). To obtain more accurate
estimates reflecting > 90% of the population, outliers were
not incorporated in statistical analysis (Figure 6). The
mean pre-treatment serum sLHCGR and LH-sLHCGR
levels in high (oocytes ≥ 15), intermediate (oocytes, 8-14))
and low responders (oocytes ≤7) are shown in Figure 6
and in Table 1. In high responders (oocytes ≥ 15), mean
sLHCGR (Figure 6a) and LH-sLHCGR (Figure 6c) levels
were significantly lower than in women who failed to
become pregnant. Similarly, women with OHSS had lower
sLHCGR/LH-sLHCGR than the corresponding non-preg-
nant women (Figure 6a & 6c). Among low responders
(oocytes ≤7), high sLHCGR/LH-sLHCGR is also signifi-
cantly associated with a lack of embryo implantation.
Levels of sLHCGR/LH-sLHCGR in women with inter-
mediate response (oocytes, 8-14) had little effect on preg-
nancy outcome (Figure 6b & 6d). However, saturation
levels of sLHCGR differed between those who achieved
p r e g n a n c ya n dt h o s ew h od i dn o t( F i g u r e4 ca n d4 d ) .
Together, these results suggest that while high serum
LHCGR/LH-LHCGR inhibit embryo implantation in high
Figure 4 Younger women among low responders to COS have
higher serum sLHCGR. Patients yielding a) ≤ 7, b) ≤ 5 and c) ≤ 4
oocytes with respect to their age were plotted. The correlation
between sLHCGR and age among high responders (≥ 15 oocytes)
with OHSS is shown (d). The correlation coefficient (r) and the level
of significance (P value) are shown for each group.
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Page 7 of 14(oocytes ≥ 15) and low responders (oocytes ≤7), women
yielding optimum number of oocytes (8-14) are unaffected
by their absolute pre-treatment sLHCGR concentrations.
As shown in Table 1, women with highest yield of average
number of oocytes experiencing OHSS (FAE), had highest
serum AMH and lowest mean FSH:LH ratio (0.9 ± 0.3).
Moreover, low responders (oocytes ≤7) had highest FSH:
LH ratio (1.9 ± 1.4).
Of 23 patients with OHSS, one became pregnant spon-
taneously, two did not participate in further treatment and
for one patient, frozen embryo transfer (FET) is scheduled
in the near future. Of the remaining patients (nineteen),
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Page 8 of 14twelve failed to become pregnant and seven were pregnant
following FET; five of the seven who became pregnant had
pre-treatment sLHCGR below 10 pmol/mL (data not
shown).
Discussion
Here we describe the development and use of two
ELISA assays that quantitatively measure sLHCGR and
sLHCGR in complex with LH (LH-sLHCGR) in human
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Page 9 of 14Table 1 A summary of the mean serum hormone concentrations (AMH, LH and FSH, FSH:LH ratio), receptor (sLHCGR) and LH-LHCGR concentrations and the
number of oocytes with respect to the fertility treatment outcome
Hormones
Receptors
Oocytes ≥ 15 Not
Pregnant N = 13
Oocytes ≥ 15
Pregnant N = 16
Oocytes ≥ 15 OHSS;
FAE N = 22
Oocytes ≤ 7 Not
Pregnant N = 38
Oocytes ≤ 7
Pregnant N = 11
Oocytes 8-14 Not
Pregnant N = 23
Oocytes 8-14
Pregnant N = 25
Number of
oocytes
16.9(± 1.1) 17.1(± 0.8) 24.4 (± 0.3) 4.2 (± 0.6) 5.0 (± 1.0) 10.9 (± 0.6) 9.8 (± 0.7)
AMH, pmol/L 19.3(± 5.2) 18.3(± 4.1) 46.6 (± 9.9) 10.1 (± 3.2) 5.6 (± 2.6) 13.3 (± 3.7) 12.9 (± 3.6)
sLHCGR, pmol/
mL
14.3(± 7.7) 7.9 (± 3.8) 9.9 (± 4.2) 16.2 (± 6.7) 6.9 (± 4.6) 19.5 (± 17.9) 15.2 (± 7.5)
LH-LHCGR,
pmol/mL
1.35(± 1.0) 0.53(± 0.4) 0.88 (± 0.6) 2.98 (± 2.1) 1.4 (± 1.0) 3.0 (± 3.67) 2.48 (± 1.6)
LH, IU/L 5.9 (± 1.0) 4.5 (± 0.9) 7.3 (± 2.7) 5.9 (± 1.2) 5.1 (± 1.1) 4.9 (± 0.7) 5.2 (± 0.8)
FSH, IU/L 6.5 (± 0.7) 6.7 (± 1.0) 6.3 (± 0.9) 9.0 (± 1.3) 9.7 (± 1.6) 7.0 (± 0.7) 7.7 (± 0.9)
FSH/LH 1.1 (± 0.7) 1.5 (± 1.1) 0.9 (± 0.3) 1.5 (± 1.0) 1.9 (± 1.4) 1.4 (± 1.0) 1.5 (± 1.1)
No Pregnancy, Pregnancy and OHSS shown in Figure 6. The numbers in parentheses are confidence intervals (± CI).
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4serum from women seeking fertility treatment. In addi-
tion to serum, these ELISA assays could quantitatively
measure sLHCGR and LH-sLHCGR in human plasma
and follicular fluids.
Serum AMH is increasingly used in fertility treatment
as an indicator of ovarian reserve. Very low (0-4 pmol/L)
and very high (≥45 pmol/L) AMH concentrations are
associated with reduced oocyte yields and PCO (risk of
OHSS) following COS, respectively [8]. Our data demon-
strate the expected correlation between AMH levels and
oocyte yield in women who exhibited OHSS and had all
embryos frozen. However, high AMH (> 39 pmol/L) was
ap o s i t i v ep r e d i c t o rf o ro n l y5 2 %( 1 2 / 2 3 )o ft h e s e
patients; the remaining 48% (11/23) had AMH values
ranging from 7.6-35 pmol/L. Regarding pregnancy, like
many other reports [23-26], we found no correlation
between AMH and the embryo implantation potential.
We have described three categories of patients seeking
fertility treatment with respect to the basal (pre-treat-
ment) serum concentrations of sLHCGR/LH-sLHCGR:
undetectable to very low (low), intermediate (optimal)
and very high. Patients who were high (oocytes ≥15) and
low responders (oocytes ≤7), had fresh transfers and
became pregnant had soluble receptor levels that were
significantly lower than those who did not become preg-
nant. Comparing pregnancy rates in low and high
responders we found that the levels of LH complexed
with sLHCGR were low in those who became pregnant
(low and high responders) and higher in those who did
not become pregnant. Although embryos were not trans-
ferred, the OHSS group (oocytes ≥15) also had low
sLHCGR/LH-sLHCGR and FSH:LH ratio. A comparison
of pregnancy rates among those producing an intermedi-
ate number of oocytes (8-14) revealed the opposite; those
who became pregnant had higher levels of LH complexed
to sLHCGR than did those who did not become preg-
nant. The results for complexed LH-sLHCGR amongst
intermediate responders were not considered statistically
significant and would require a larger study to verify a
significant difference. Nevertheless, we believe that this
observation merits discussion because, if verified, it could
indicate that an optimum saturation level of sLHCGR
that correlates with oocyte yields, is important for preg-
nancy. Moreover, if verified, this result might suggest an
important biological function for sLHCGR in modulating
LH availability, e.g. by acting as an LH reservoir as
observed for IL-4 and growth hormone and tumor necro-
sis factor receptors [27-30]
Given that the production of soluble polypeptide hor-
mone and cytokine receptors is regulated by alternative
splicing, protease activation, secretion of membrane vesi-
cles [31], ligand-mediated receptor activation [15] and
stress [19], the higher concentrations of the sLHCGR/LH-
sLHCGR that we have observed could be attributed to
infection, endometriosis, ovarian and adrenal pathology,
obesity, insulin resistance and other metabolic diseases.
Notably, a recent report suggests hCG stimulates LHCGR
expression in lymphocyte during controlled ovarian stimu-
lation and is linked to improved implantation [32] On the
other hand, undetectable to low circulating sLHCGR/LH-
sLHCGR might reflect reduced hormonal activation and
down regulation of sLHCGR synthesis as observed in
Down’s syndrome placenta [33,34]. This may suggest that
like other cytokine and hormone receptors [27-30], the
production of sLHCGR is regulated.
What could be the patho-physiological significance of
sLHCGR in the context of COS and implantation of the
embryo? There are two possible mutually non-exclusive
ways the sLHCGR could affect the LH/hCG functions:
sLHCGR is intrinsically a specific serum binding protein
[28-30] which stabilizes or prevents degradation of the
LH/hCG until the hormone is delivered to the traditional
membrane-bound receptor. In extreme conditions (low or
undetectable sLHCGR), leading to OHSS and high
response might reflect an unregulated burst of stimulation
resulting from hormonal induction. This is consistent with
fast and slow disappearance (double exponential curves) of
LH and hCG reported a few decades ago [35]. Accord-
ingly, very short serum half-life of variably glycosylated LH
(20-80 min, [35,36]) compared to FSH (several hrs, [37])
and hCG (1-3 days, [38]) suggests that combined and sus-
tained LH-FSH induction of ovarian functions would
require receptor-mediated stabilization, specifically of LH
enhancing its resistance to clearance. Therefore, in addi-
tion to OHSS, our data demonstrate the increased release
of oocytes (≥ 15) on COS is associated with low sLHCGR/
LH-sLHCGR concentrations (Figure 5 and Table 1). The
possibility that an optimal level of sLHCGR complexed
with LH exists that promotes pregnancy in those produ-
cing 8-14 oocytes might support a physiological reservoir
role for sLHCGR in regulating LH availability. In an alter-
native scenario [27,39,40] the mobile sLHCGR may com-
pete with membrane-associated counterparts for binding
to circulating LH/hCG. Therefore, increased levels of
serum sLHCGR modulate the LH/hCG activity by inhibit-
ing their interactions with cell surface receptors. In gen-
eral, high serum sLHCGR concentrations are linked to
reduced production of oocytes as well as poor implanta-
tion (Figures 5, 6 and Table 1). This could be again linked
to the inhibitory effect of circulating sLHCGR on LH/hCG
functions.
Pre-treatment serum sLHCGR/LH-sLHCGR and LH
levels could provide an indication of functional LH levels
that would allow the adjustment of hormone dose prior to
ovarian induction. This could be an important step
towards avoidance of OHSS, particularly for patients
whose AMH levels do not correlate with high oocyte yield
and potential OHSS. It should be emphasized that we
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trations and that during fertility treatment and prior to
embryo transfer, these concentrations could alter. Indeed,
this might explain both positive and failed implantation
when the pre-treatment serum LH receptor concentra-
tions in some women were high and low, respectively (Fig-
ure 6). Therefore, the true effect of circulating sLHCGR in
modulating implantation and early pregnancy would
require its estimation before and immediately after embryo
transfer. Future experiments are needed to test this
hypothesis.
Critical clinical parameters that predict reduced response
to COS are age, BMI, early cycle FSH, LH, inhibin B, antral
follicle counts (AFC) and AMH concentrations [5,41]. Of
these, serum AMH and AFC are recognized as superior
predictors of ovarian reserve and OHSS [8]. Our study
indicates that in the absence of AMH data, measurement
of pre-treatment circulating sLHCGR/LH-sLHCGR
together with FSH:LH ratios, age and AFC might provide
sufficient information on aberrant ovarian response to
establish individualized hormone combinations, daily doses
and duration of treatment prior to COS.
The improvement of pregnancy outcome could be
another potential benefit of measuring pre-treatment
serum sLHCGR. Following a decline in LH support, hCG
is the foremost leutotropic paracrine signal produced by
the embryo, well before the implantation begins [7]. This
hCG signaling critically influences the blastocyst develop-
ment, uterine receptivity through stromal fibroblast prolif-
eration, secretion of IGF binding protein-1, NK cell
activation and apoptosis (Fas-FasL), transient immune tol-
erance through activation of regulatory T-cells and dendri-
tic cells (MHC class II, IL-10 and IDO expression), and
endometrial angiogenesis through secretion of VEGF
[42,43]. Furthermore, an increased LH surge is associated
with a high rate of miscarriage [44]. Therefore, measure-
ment of sLHCGR/LH-sLHCGR following embryo transfer
together with targeted hCG therapy could improve preg-
nancy outcome by extending the window of implantation
and simultaneously reducing the frequency of miscarriage.
The bioactive serum/plasma LH concentrations, con-
ventionally measured by Leydig cell assay [45] have been
shown to be significantly lower than the immunoreactive
hormone in various clinical conditions affecting ovarian
functions and fertility [46,47]. Whether the ELISA assays
described here for measuring the soluble LH receptor
and the hormone-receptor complex would be compar-
able to the Leydig cell assay with respect to LH bioactiv-
ity requires a separate investigation. The link between
hypogonadism and LHCGR functions was first demon-
strated by partial purification of Mr 30 K-60 K serum
proteins that were found to competitively inhibit the hor-
mone binding to the LH receptor and affect testosterone
production in uremic boys [48].
Conclusions
Two hormones, LH and hCG use a common cell-surface
receptor, known as LHCGR, to transmit signals into
cells. Although this receptor is normally tethered to the
surface of a cell, new variants (sLHCGR) have been
found circulating in the blood. These variants do not
transmit signals but may potentiate or inhibit LH and
hCG functions. Our group has developed novel assays to
measure the level of sLHCGR and LH-sLHCGR complex
in women seeking IVF treatment. It was found that those
who produced a few oocytes (less than 7) or many
oocytes (more than 15), had low concentrations of
sLHCGR and a good IVF outcome (i.e. pregnancy),
whereas a high level of sLHCGR within these two groups
was indicative of a poor IVF outcome (i.e. not pregnant).
For those producing an intermediate number of oocytes
(8-14) the levels of sLHCGR did not appear to affect
pregnancy. These new tests could be useful in avoiding
ovarian hyperstimulation and may help circumvent a
situation where all embryos need to be frozen. Moreover,
if used before uterine transfer of the embryo, these assays
may also identify those women who may benefit from
short-term supplementation with hCG in order to firmly
establish the pregnancy.
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